Anti-Human CD105/ENG Monoclonal Antibody (1A609)

Introduction to Anti-Human CD105/ENG Monoclonal Antibody (1A609)

Anti-Human CD105/ENG Monoclonal Antibody (1A609) is a monoclonal antibody that specifically targets the human CD105/ENG protein. This protein is also known as endoglin and is a type I integral membrane glycoprotein. CD105/ENG is primarily expressed on the surface of endothelial cells, which are cells that line the interior of blood vessels. It plays a crucial role in angiogenesis, the process of forming new blood vessels from pre-existing ones. The overexpression of CD105/ENG has been linked to various diseases, making it an important target for therapeutic interventions. In this article, we will discuss the structure, activity, and application of Anti-Human CD105/ENG Monoclonal Antibody (1A609).

Structure of Anti-Human CD105/ENG Monoclonal Antibody (1A609)

Anti-Human CD105/ENG Monoclonal Antibody (1A609) is a monoclonal antibody that is produced by hybridoma technology. It is a chimeric antibody, meaning it is composed of both human and mouse components. The antibody consists of two heavy chains and two light chains, each with a variable region that binds specifically to the CD105/ENG protein. The constant regions of the antibody are responsible for effector functions such as complement activation and antibody-dependent cell-mediated cytotoxicity.

Activity of Anti-Human CD105/ENG Monoclonal Antibody (1A609)

Anti-Human CD105/ENG Monoclonal Antibody (1A609) binds specifically to the CD105/ENG protein on the surface of endothelial cells. This binding inhibits the interaction of CD105/ENG with its ligands, such as transforming growth factor-beta (TGF-β) and bone morphogenetic protein (BMP). This results in the suppression of angiogenesis, as CD105/ENG is a crucial co-receptor for TGF-β and BMP signaling pathways. Additionally, the binding of Anti-Human CD105/ENG Monoclonal Antibody (1A609) to CD105/ENG on endothelial cells can induce antibody-dependent cell-mediated cytotoxicity, leading to the destruction of these cells.

Applications of Anti-Human CD105/ENG Monoclonal Antibody (1A609)

1. Cancer therapy: CD105/ENG is overexpressed on the surface of endothelial cells in various types of cancer, including breast, lung, and prostate cancer. Anti-Human CD105/ENG Monoclonal Antibody (1A609) has shown promising results in preclinical studies as a potential therapy for these cancers. It inhibits tumor growth by suppressing angiogenesis and also induces antibody-dependent cell-mediated cytotoxicity, leading to the destruction of tumor-associated endothelial cells.

2. Anti-inflammatory therapy: Inflammation plays a crucial role in the development and progression of various diseases, including autoimmune diseases and chronic inflammatory conditions. CD105/ENG has been identified as a key regulator of the inflammatory response. Anti-Human CD105/ENG Monoclonal Antibody (1A609) has been shown to inhibit the production of pro-inflammatory cytokines and reduce the severity of inflammation in preclinical studies.

3. Cardiovascular diseases: CD105/ENG is highly expressed on the surface of endothelial cells in atherosclerotic plaques, which are a major cause of cardiovascular diseases. Anti-Human CD105/ENG Monoclonal Antibody (1A609) has been shown to reduce the size of atherosclerotic plaques and improve the function of blood vessels in animal models, making it a potential therapy for cardiovascular diseases.

4. Tissue regeneration: CD105/ENG is also involved in tissue repair and regeneration. Anti-Human CD105/ENG Monoclonal Antibody (1A609) has been shown to promote the recruitment of stem cells to damaged tissues and enhance tissue repair in preclinical studies. This makes it a potential therapy for various tissue injuries and diseases.

Conclusion

Anti